Background: Metastatic colorectal cancer (mCRC) is a major health burden worldwide and a growing challenge in Asian countries. Treatment options include chemotherapy and a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab) or anti-epidermal growth factor receptor (EGFR) therapy. Aflibertcept, a recombinant fusion protein, is approved for the treatment of mCRC in combination with FOLFIRI in patients with disease progression during or after an oxaliplatin-containing regimen, based on its efficacy and tolerability profile in clinical trials. Hence, the amount and dosage and side effects of chemotherapy – even though are highly reduced - still are a counted as a great challenge. The purpose of this report is to provide an insight of the future production of a drug delivery system which can be sustainable, targeted and has less side effects. In order of achieving these goals, a DDS system was designed using electrospining method and nanoparticles filled with Aflibercept.